FDA to Address Female Sexual Enhancement Drugs

LOS ANGELES — The topic of female sexual dysfunction — and drugs to treat it — will be front and center at an FDA meeting this month, one in a series of 20 looking at “patient-focused drug development.”

Critics have accused the Food and Drug Administration of having a gender bias, pointing out that it has approved six male-targeted drugs to help them overcome anxiety, physiology and more to get an erection, but has yet to approve a single female equivalent. 

The meeting to be held Oct. 27-28 will include statements from patients about the impact that female sexual dysfunction has had on their lives, WebMD reports. It will also include a scientific workshop to discuss how to diagnose the disorder and measure how well medications for it work.

Advocating for pharmaceutical gender inclusivity is Even the Score, a campaign that launched in June and is backed by the drug companies of at least three potential treatments for female sexual dysfunction.

A petition to the FDA posted by Even the Score on Change.org attracted more than 16,000 signatures. The petition addresses the FDA: “We urge you to work fairly and urgently toward a solution to an unmet medical need…”

Others, including the National Women’s Health Network and the American Medical Women’s Association, believe that the dearth of pharmaceutical options for women is not a gender bias, but a reflection of how much more complicated treating female sexual dysfunction can be.  

Following, they have supported the FDA’s decisions not to approve a drug for female sexual dysfunction, arguing that women may need more than a single pill to boost their libido. Viagra and Cialis target one important aspect of sex — the erection — but do not address psychological aspects of arousal, which may be key for women’s satisfaction,

Cindy Pearson, executive director of the National Women’s Health Network, says while the FDA has not been immune to gender bias, she doesn’t believe that is what’s delaying the drugs. “If it were gender bias, we would be yelling and screaming,” Pearson said. “The problem is the drugs. Our biology is so much more complicated than men’s.”

Related:  

Copyright © 2026 Adnet Media. All Rights Reserved. XBIZ is a trademark of Adnet Media.
Reproduction in whole or in part in any form or medium without express written permission is prohibited.

More News

'Group C' to Debut 'Woodman Casting X' Board Game

Gaming company Group C will debut its new industry-themed board game, “Woodman Casting X — The Game,” later this year.

Hankey's Toys Unveils 'Peak' Prostate Dildo

Mr. Hankey's Toys has debuted the Peak, its new P-spot-targeting prostate dildo.

Kheper Releases 'Ride My Dick' Tickets

Kheper Games has debuted its new "Ride My Dick" sex act novelty coupons.

SVibe Debuts 'Jovi Arc' Vibrating Cock Ring

SVibe has introduced the new remote-controlled Jovi Arc vibrating cock ring.

Blush Introduces 2 New Vibrating Wands

Blush has debuted two new oscillating wand vibrators, Juno and Sage.

XBIZ Retail Retreat Miami Set for May 4-8

The summer edition of XBIZ Retreat will take place May 4-8, welcoming attendees back to the Grand Miami Beach Hotel’s oceanfront setting and marking the latest installment of the all-inclusive, invitation-only B2B retail event.

Orion Expands 'Beau Coeur' Collection

Orion Wholesale has introduced five new pleasure products from its Beau Coeur collection.

Orion Debuts 'Masturbator 11'

Orion Wholesale has introduced Masturbator 11 from its What You Never Expected (WYNE) line.

Tenga Debuts 2 New Vibrating Cock Rings

Pleasure brand Tenga has introduced its new paiRING and paiRING+ vibrating cock rings.

Calvista Now Shipping 'Romp' Line From WOW Tech

Calvista has reintroduced WOW Tech’s Romp line of pleasure products to the Australian and New Zealand markets.

Show More